Jazz Pharmaceuticals CEO Renee Gala Sells $472K in Shares Under 10b5-1 Plan

Insider Transaction Overview

On October 6, 2026, Renee D. Gala, President & CEO and Director of Jazz Pharmaceuticals plc ($JAZZ), executed a sale of 2,000 ordinary shares at a price of $236.40 per share, generating total proceeds of $472,800.00.

Key Transaction Highlights

• Insider Name: Renee D. Gala
• Role: President & CEO, Director
• Security: Ordinary Shares
• Transaction Type: Open Market Sale (Code S)
• Shares Sold: 2,000
• Price per Share: $236.40
• Gross Value: $472,800.00
• Shares Held Following Transaction: 141,394 ordinary shares

Rule 10b5-1 Trading Plan Context

The transaction was executed automatically pursuant to a pre-arranged Rule 10b5-1 trading plan adopted by Ms. Gala on June 4, 2026. Because the sale was non-discretionary and scheduled in advance, it does not reflect spontaneous market sentiment or real-time views on company valuation.

Impact and Ownership Assessment

The disposition represents approximately 1.4% of Ms. Gala's total reported holdings prior to the trade (143,394 shares down to 141,394 shares). Given the modest size of the sale relative to her retained position and the presence of a pre-established 10b5-1 plan, this transaction carries Low overall trading significance.